| Causes and consequences of snake venom variation NR Casewell, TNW Jackson, AH Laustsen, K Sunagar Trends in pharmacological sciences 41 (8), 570-581, 2020 | 309 | 2020 |
| Basics of antibody phage display technology L Ledsgaard, M Kilstrup, A Karatt-Vellatt, J McCafferty, AH Laustsen Toxins 10 (6), 236, 2018 | 275 | 2018 |
| Pros and cons of different therapeutic antibody formats for recombinant antivenom development AH Laustsen, JM Gutiérrez, C Knudsen, KH Johansen, ... Toxicon 146, 151-175, 2018 | 186 | 2018 |
| Bee updated: current knowledge on bee venom and bee envenoming therapy MB Pucca, FA Cerni, IS Oliveira, TP Jenkins, L Argemí, CV Sørensen, ... Frontiers in immunology 10, 2090, 2019 | 182 | 2019 |
| Unveiling the nature of black mamba (Dendroaspis polylepis) venom through venomics and antivenom immunoprofiling: Identification of key toxin targets for antivenom development AH Laustsen, B Lomonte, B Lohse, J Fernández, JM Gutiérrez Journal of proteomics 119, 126-142, 2015 | 144 | 2015 |
| From fangs to pharmacology: the future of snakebite envenoming therapy A H Laustsen, M Engmark, C Milbo, J Johannesen, B Lomonte, ... Current Pharmaceutical Design 22 (34), 5270-5293, 2016 | 138 | 2016 |
| Scorpion venom: detriments and benefits S Ahmadi, JM Knerr, L Argemi, KCF Bordon, MB Pucca, FA Cerni, ... Biomedicines 8 (5), 118, 2020 | 135 | 2020 |
| In vivo neutralization of dendrotoxin-mediated neurotoxicity of black mamba venom by oligoclonal human IgG antibodies AH Laustsen, A Karatt-Vellatt, EW Masters, AS Arias, U Pus, C Knudsen, ... Nature communications 9 (1), 3928, 2018 | 135 | 2018 |
| History of envenoming therapy and current perspectives MB Pucca, FA Cerni, R Janke, E Bermúdez-Méndez, L Ledsgaard, ... Frontiers in immunology 10, 1598, 2019 | 130 | 2019 |
| Animal immunization, in vitro display technologies, and machine learning for antibody discovery AH Laustsen, V Greiff, A Karatt-Vellatt, S Muyldermans, TP Jenkins Trends in Biotechnology 39 (12), 1263-1273, 2021 | 113 | 2021 |
| Exploring the venom of the forest cobra snake: Toxicovenomics and antivenom profiling of Naja melanoleuca LP Lauridsen, AH Laustsen, B Lomonte, JM Gutiérrez Journal of proteomics 150, 98-108, 2017 | 108 | 2017 |
| Selecting key toxins for focused development of elapid snake antivenoms and inhibitors guided by a Toxicity Score AH Laustsen, B Lohse, B Lomonte, M Engmark, JM Gutiérrez Toxicon 104, 43-45, 2015 | 106 | 2015 |
| Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease? AH Laustsen, KH Johansen, M Engmark, MR Andersen PLoS neglected tropical diseases 11 (2), e0005361, 2017 | 103 | 2017 |
| Advances in antibody phage display technology L Ledsgaard, A Ljungars, C Rimbault, CV Sørensen, T Tulika, J Wade, ... Drug Discovery Today 27 (8), 2151-2169, 2022 | 102 | 2022 |
| Innovative immunization strategies for antivenom development E Bermúdez-Méndez, A Fuglsang-Madsen, S Føns, B Lomonte, ... Toxins 10 (11), 452, 2018 | 93 | 2018 |
| Snake venomics of monocled cobra (Naja kaouthia) and investigation of human IgG response against venom toxins AH Laustsen, JM Gutiérrez, B Lohse, AR Rasmussen, J Fernández, ... Toxicon 99, 23-35, 2015 | 91 | 2015 |
| Biosynthetic oligoclonal antivenom (BOA) for snakebite and next-generation treatments for snakebite victims RM Kini, SS Sidhu, AH Laustsen Toxins 10 (12), 534, 2018 | 89 | 2018 |
| Toxicovenomics and antivenom profiling of the Eastern green mamba snake (Dendroaspis angusticeps) LP Lauridsen, AH Laustsen, B Lomonte, JM Gutiérrez Journal of proteomics 136, 248-261, 2016 | 88 | 2016 |
| Biotechnological trends in spider and scorpion antivenom development AH Laustsen, M Solà, EC Jappe, S Oscoz, LP Lauridsen, M Engmark Toxins 8 (8), 226, 2016 | 84 | 2016 |
| Toxin synergism in snake venoms AH Laustsen Toxin Reviews 35 (3-4), 165-170, 2016 | 75 | 2016 |